Adma Biologics (ADMA) closed the last trading session at $5.99, gaining 13.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8 indicates a 33.6% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $1.63. While the lowest estimate of $6 indicates a 0.2% increase from the current price level, the most optimistic analyst expects th ...